Weight Gain After Ozempic: Why It Happens and What Actually Helps

By Brandon, founder of Ozzi · Published August 21, 2026

Weight gain after Ozempic happens because the drug replaces a hormone signal your body stops sending on its own after weight loss. When the injection stops, ghrelin stays high and satiety hormones stay low, so hunger returns fast. Trial data shows roughly two-thirds of lost weight comes back within a year.

How much weight do people actually regain after stopping?

We have a clean number for this, and it comes from the extension of the STEP 1 trial published in Diabetes, Obesity & Metabolism.

The setup: 1,961 adults took once-weekly semaglutide 2.4mg or placebo for 68 weeks. Then everything stopped, including the lifestyle program. Researchers followed 327 of them for another full year.

Over the 68 weeks on treatment, the semaglutide group lost 17.3% of their body weight. In the year after stopping, they regained 11.6 percentage points of that loss. Net result at week 120: 5.6% below where they started.

So roughly two-thirds came back. The cardiometabolic improvements went with it. Blood pressure, lipids, and glycemic markers drifted back toward baseline for most variables.

A 2026 review in the same journal pooled randomized withdrawal trials and real-world cohorts covering more than 289,000 patients. Their range for weight regain after discontinuation: 60% to 90% within one year. That review also found glycemic, blood pressure, and lipid parameters return to baseline in about 12 months.

Two-thirds of the weight came back in twelve months. That's the trial average, not the worst case.

Why does the hunger come back so fast?

This is the part that gets explained badly, and it's the part that matters most.

When you lose a significant amount of weight, your body changes its hormonal defense of that weight. The landmark study here is Sumithran and colleagues in the New England Journal of Medicine. They put 50 people through a 10-week very-low-energy diet, measured nine appetite hormones, and then measured again at 62 weeks.

After the weight loss, ghrelin (the hormone that drives hunger) went up. Leptin, peptide YY, and cholecystokinin (the hormones that signal fullness) went down. Subjective appetite went up.

Here's the finding that reframes everything: one full year later, those hormone levels had not returned to baseline. Ghrelin was still elevated. Satiety hormones were still suppressed. Hunger ratings were still significantly higher than before the weight loss.

Your cravings aren't really a willpower problem, they're a hormone problem. That's true for anyone who has lost weight, and a GLP-1 medication sits directly on top of it.

While you're on the injection, a pharmaceutical GLP-1 agonist is doing the satiety signaling for you at a dose far above what your body produces. Stop the injection and that signal disappears in weeks. Underneath it, the post-weight-loss hormone environment is still there, still pushing hunger up. The 2026 review describes this as reactivation of orexigenic pathways plus adaptive thermogenesis.

That's why people describe appetite coming back "doubled." One Ozzi customer put it exactly that way in our post-purchase survey: "Was on a GLP1 med for a year. Lost 30 lbs. Immediately after stopping my appetite doubled and I'm finding it very hard to not overeat."

What does the regain timeline look like?

Individual results vary a lot. But the shape of the curve is consistent across trials: fastest in the first three months, then steady.

Why does the weight come back as fat?

This one deserves more attention than it gets.

A review in Diabetes Care looked at body composition on incretin therapies. GLP-1 and dual agonist medications produce large weight loss, and a meaningful share of it is lean mass: roughly 10%, or around 6kg. The authors compare that to a decade or more of normal aging.

Muscle is metabolically active tissue. Lose it, and your resting energy expenditure drops. Regain weight without regaining muscle, and you land at the same scale number with a worse body composition than you started with.

The same review makes the constructive point: supervised resistance training for more than 10 weeks can add about 3kg of lean mass and roughly 25% in strength. The authors propose that holding onto lean mass during treatment may blunt fat regain after stopping.

If you're planning a transition, resistance training and protein intake move the needle more than anything else on the list, and they should start before your last dose, not after.

Can you support your own GLP-1 production instead?

Your body makes GLP-1 on its own, from L-cells in the intestinal lining, in response to what you eat. That system doesn't disappear when you stop an injection. It's still there, and it responds to inputs.

Three of those inputs have real human evidence behind them.

Viscous fiber. Glucomannan from konjac root absorbs water and expands in the stomach, which promotes fullness through simple physical volume. A network meta-analysis of 111 randomized trials in Pharmacological Research found glucomannan produced a mean weight difference of 1.36kg versus control. Modest on its own, and it stacks with everything else here.

Prebiotic fiber. Chicory root inulin feeds the gut bacteria that ferment fiber into short-chain fatty acids. That fermentation is how your gut produces butyrate naturally.

Butyrate. This is the interesting one. Butyrate is a postbiotic, the primary fuel for the cells lining your colon, and it supports gut barrier function. In mouse and cell studies, butyrate stimulates the L-cells that secrete GLP-1. Human confirmation is still pending, so treat that as the proposed mechanism rather than a settled human finding.

What we do have in humans is delivery data. A 2025 crossover trial in healthy adults compared three butyrate forms at a matched dose and measured serum butyrate directly. L-lysine butyrate (the BIOMEnd form) reached peak serum butyrate at 20 minutes, roughly 5 times the peak of tributyrin. It was also rated the most palatable form in organoleptic testing.

Ozzi uses both routes at once: 500mg of L-lysine butyrate directly, plus 500mg of chicory root inulin to feed your own butyrate-producing bacteria.

The injection replaced the signal. The goal now is to support the system that makes it.

What should you actually do about it?

Talk to your prescriber first. Everything below assumes you've already made the decision with them.

1. Start the habits before the last dose. Protein target, resistance training, and sleep should be running for at least a month before you taper. Building them while appetite is still suppressed is far easier than building them after.
2. Protect muscle. Resistance training two to three times a week. Protein at every meal. This is the single biggest lever on what the regain looks like.
3. Plan for the evenings. Nighttime is where it shows up first. About 45% of our customers name after-dinner snacking as their main problem, and they're not people with weak discipline.
4. Support the natural pathway daily. Fiber, prebiotics and butyrate work by consistency, not by dose spikes.
5. Weigh weekly, not daily. Some regain is water and glycogen. Weekly averages tell you the real trend.
6. Decide your line in advance. Pick the number where you'd talk to your doctor about restarting. Deciding it now beats deciding it in a bad moment.

Is stopping still worth it?

For a lot of people, yes, and the trial data supports that.

Look at the STEP 1 extension number again. After a full year off treatment, participants were still 5.6% below their starting weight. That's a real result that persisted with no drug and no active lifestyle program.

Cost is the most common reason people stop. Access is second. In a cohort of 125,474 US adults published in JAMA Network Open, 64.8% of people without type 2 diabetes had discontinued within one year. If you're stopping, you are firmly in the majority.

The people who do best are the ones who treat it as a planned transition with a support system in place, rather than an ending.

Related reading

• Quitting Ozempic: how to transition off GLP-1 drugs
• The rebound effect: long term GLP-1 usage issues
• GLP-1 and muscle loss
• What is food noise?
• Butyrate and GLP-1
• Lost your GLP-1 insurance coverage?
• What is GLP-1?

References

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
2. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. https://doi.org/10.1056/NEJMoa1105816
3. Shah E, et al. Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP-1 receptor agonists. Diabetes Obes Metab. 2026;28(6):4546-4558. https://doi.org/10.1111/dom.70713
4. Locatelli JC, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718-1730. https://doi.org/10.2337/dci23-0100
5. Rodriguez PJ, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349
6. Shahinfar H, et al. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: a systematic review and network meta-analysis of 111 randomized clinical trials. Pharmacol Res. 2023;196:106944. https://doi.org/10.1016/j.phrs.2023.106944
7. Thomsen RW, et al. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66-88. https://doi.org/10.1111/dom.16364
8. La Monica MB, et al. Comparative pharmacokinetics of three butyrate supplements in healthy adults. J Exerc Nutr. 2025;8(1):4. NCT06700785.

This article is for general information and is not medical advice. Ozzi is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Never start, stop or change a prescription medication without talking to your healthcare provider.